Amarin Corporation plc (AMRN) Earnings Call Analysis

NASDAQ · Healthcare · Drug Manufacturers - General

Earnings Reports

• Ameren (AMRN) Q2 2026: International VSCEPA Demand Jumps 59%, Restructuring Delivers Leaner Model
  July 29, 2026
• Ameren (AMRN) Q1 2026: Operating Expenses Down 31% as Restructuring Delivers Margin Reset
  April 29, 2026
• Ameren (AMRN) Q4 2025: $36M Restructuring Drives 41% OPEX Cut as Partnered Model Takes Hold
  February 25, 2026
• Ameren (AMRN) Q3 2025: Operating Margin Improves 38 Points as Partnered Model Takes Hold
  October 29, 2025
• Ameren (AMRN) Q2 2025: $70M Cost Reset and Recordati Deal Reshape Global Margin Trajectory
  August 05, 2025
• Ameren (AMRN) Q3 2024: European Revenue Jumps $3.5M as U.S. Generic Pressures Mount
  October 30, 2024
• Ameren (AMRN) Q2 2024: European Net Product Revenue Climbs $2.9M as U.S. Faces Formulary Loss
  July 31, 2024
• Amarin (AMRN) Q1 2024: Europe In-Market Sales Surge 65% as IP Protection Extends to 2039
  May 01, 2024
• Ameren (AMRN) Q4 2023: Europe Product Revenue Jumps 65% as Global Expansion Drives Optionality
  February 29, 2024

Browse all companies